2019 - Pharma Rep Focus

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal

MedCity News

MARCH 31, 2025

This program came from a $950 million acquisition in 2019 that marked Vertexs entry into type 1 diabetes. Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals.

Pharmaceutical

Pharmaceutical Medical Biopharma Pharma

HHS: Younger Adults, Latino Individuals Showed Gains in Coverage From 2019 to 2021

MedCity News

JANUARY 17, 2023

in 2019, according to a recent report from HHS. The uninsured rate declined to 10.5% in 2021 from 11.1% Some of the largest gains in coverage were among demographic groups that historically have had higher uninsured rates, such as younger adults, Latino individuals, American Indian/Alaska Natives and non-English speaking adults.

Insurance

Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation

MedCity News

JANUARY 16, 2025

Galapagos and Gilead Sciences have both evolved since inking their R&D collaboration agreement in 2019. Separating Galapagos into two offers a way for that company to pursue its cell therapy strategy while also keeping the Gilead alliance alive, executives from both companies said.

Biopharma

Biopharma Pharma

Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023

MedCity News

FEBRUARY 25, 2025

Medicare Part D spending on 10 diabetes drugs increased 364% between 2019 and 2023. The post Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023 appeared first on MedCity News.

Forrester Research Report: How Sales and Marketing Intelligence Drive Improved Business Outcomes

Advertiser: ZoomInfo

In 2019, DiscoverOrg commissioned Forrester Consulting to evaluate sales and marketing intelligence practices in the B2B space. Fact: Only 8% of sales and marketing professionals say their data is between 91% - 100% accurate. The primary takeaway? Forrester found “only 1.2%

Sales

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Fierce Pharma

DECEMBER 14, 2023

Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.

Biopharma

Merck Neuroscience Acquisition Brings a Startup With Parkinson’s, ALS Programs

MedCity News

NOVEMBER 21, 2023

One of those programs addresses a target that was the focus of a different startup purchased by Merck in 2019. Merck’s acquisition of Caraway Therapeutics adds programs for genetically defined neurodegenerative diseases.

Biopharma

Biopharma Pharma

Blue Shield of California Adds Virta Health to Network for Diabetes Care

MedCity News

FEBRUARY 7, 2023

The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California’s Wellvolution, a platform of digital lifestyle apps.

Networking

Networking Insurance

Medicaid MCOs Denied 1 out of 8 Prior Authorization Requests in 2019

MedCity News

JULY 19, 2023

Medicaid managed care organizations deny prior authorization requests at high rates, according to a recent report by the Office of Inspector General. Of the 115 MCOs the OIG analyzed, 12 had prior authorization denial rates above 25%.

Management

The 2019 Technographic Data Report for B2B Sales Organizations

Advertiser: ZoomInfo

In this report, ZoomInfo substantiates the assertion that technographic data is a vital resource for sales teams. In fact, the majority of respondents agree—with 72.3% reporting that technographic data is either somewhat important or very important to their organization.

B2B Sales

Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies

MedCity News

FEBRUARY 16, 2024

The collaboration combines this tech with a platform from Xyphos Biosciences, a cell therapy developer that Astellas acquired in 2019. Astellas Pharma is working with Kelonia Therapeutics, a startup that develops in vivo CAR T-therapies with technology that precisely delivers genetic cargo to cells.

Pharma

Pharma Biopharma

AstraZeneca’s Rare Disease Pipeline Notches Another FDA Approval

MedCity News

APRIL 1, 2024

Alexion, now AstraZeneca’s rare disease subsidiary, added the small molecule to its pipeline via a 2019 acquisition. The FDA approved AstraZeneca drug Voydeya as an add-on to standard therapies for paroxysmal nocturnal hemoglobinuria, a rare blood disorder.

FDA

FDA Biopharma Pharma

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma

Biopharma Leads Pharma

Boom, Now Bust: Budget Cuts and Layoffs Take Hold in Public Health

MedCity News

SEPTEMBER 6, 2024

Local health department staffing grew by about 19% from 2019 to 2022, according to a report from the National Association of County and City Health Officials that studied 2,512 of the nation’s roughly 3,300 local departments.

Safety

CVS Health reports 15.7% reduction in suicide attempts among Aetna members

MedCity News

SEPTEMBER 27, 2022

decrease in suicide attempts in 2022, compared to 2019. Among CVS Health’s adult members, there was a 34.1% However, there was a 32% increase among adolescents, largely due to challenges from Covid-19. In response, CVS Health is expanding its resources with new initiatives that focus on adolescents.

Equip Expands Care to Adults, Banks Investment From General Catalyst

MedCity News

SEPTEMBER 22, 2023

San Diego-based Equip, which was founded in 2019, previously focused on those ages 6 to 24. The startup is now expanding to serve people of all ages, it announced Tuesday.

Lung cancer deaths decline but.

World of DTC Marketing

FEBRUARY 17, 2022

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. In 2019, nearly 14 of every 100 U.S.

Medicine

Medicine Insurance Leads Medical

Vanda's jet-lag approval hopes for Hetlioz quashed with FDA hearing rejection

Fierce Pharma

MARCH 5, 2024

Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. Vanda has been waiting years for an FDA hearing to contest the agency’s 2019 rejection of its sleep drug Hetlioz in jet lag disorder. regulator, the FDA has crushed Vanda’s bid.

FDA

New FDA Nod for Roche Drug Moves It to the Front Line in Treating Blood Cancer

MedCity News

APRIL 19, 2023

Accelerated approval of the drug in 2019 had made the drug a third treatment option for patients with advanced cases of this type of blood cancer. Roche’s Polivy is now approved as an earlier line of treatment for patients who have diffuse large B-cell lymphoma.

FDA

FDA Patients Biopharma Pharma

MA Beneficiaries Have Fewer In-Network Options for Psychiatrists Than Other Insurance Types

MedCity News

JULY 6, 2023

A Health Affairs study discovered that nearly two-thirds of Medicare Advantage psychiatrist networks, or 64.6%, were narrow in 2019. Comparatively, about 43.1% of Medicaid managed care networks were narrow and 39.5% of ACA Marketplaces were narrow.

Networking

Networking Insurance Management

Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejection

Fierce Pharma

APRIL 23, 2024

Dating to a 2019 clinical hold of a phase 3 trial, getting its gene therapy ra | Dating to a 2019 clinical hold, getting its gene therapy pz-cel across the FDA finish line has been a challenge for troubled Abeona Therapeutics. Now the wait continues as the FDA has rejected the treatment due to CMC issues.

FDA

BCBS Minnesota, Minnesota Oncology Achieve 10% Cost Reduction Through Value-based Contract

MedCity News

DECEMBER 22, 2022

Blue Cross and Blue Shield of Minnesota formed a value-based arrangement with Minnesota Oncology in 2019. Preliminary data show that it led to a reduction in the total cost of care, emergency visits and inpatient admissions.

BCBS Massachusetts Ramps Up Mental Health Services After Seeing Visits Double

MedCity News

DECEMBER 1, 2022

In the third quarter of 2022, BCBS Massachusetts’ members had about 8 million behavioral health visits, compared to about 4 million in 2019. In response, the insurer is expanding its mental health services by contracting with Talkiatry, And Still We Rise and DynamiCare.

Insurance

Daybreak Health Snags $13M For School-Based Mental Health Services

MedCity News

AUGUST 8, 2023

The company has partnered with more than 60 public school districts since it began providing care in 2019. Daybreak Health — a startup that partners with school districts to provide children with virtual mental health services — recently closed a $13 million Series B funding round.

Sage, Biogen Drug Is Now the First Approved Oral Med for Postpartum Depression

MedCity News

AUGUST 4, 2023

Sage Therapeutics’ Zurzuvae is the biotech’s second FDA approved product for postpartum depression, following the 2019 nod for IV-infused Zulresso. But in a blow to the multi-billion dollar partnership between Sage and Biogen, Zurzuvae did not win an additional approval in major depressive disorder.

FDA

FDA Biopharma Pharma

NIH spending for drugs approved 2010-2019 lower than industry spending, study finds

European Pharmaceutical Review

JULY 17, 2023

billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. million publications describing basic or applied research related to 386 of 387 drugs approved 2010-2019 with $8.1 This was ~10 percent of reported industry spending. billion (3.3

Food and Drug Administration

Food and Drug Administration Training Pharmaceutical Food

Mass General Brigham-Born Revenue Cycle Company Snags $55M

MedCity News

FEBRUARY 28, 2023

The company, which was launched out of Mass General Brigham in 2019, is focused on simplifying the complicated process of translating patient records into codes for billing and clinical research. CodaMetrix, an AI platform for hospital revenue cycle management, recently closed a $55 million Series A funding round.

Management

Management Patients Medical

Congressman Launches Investigation into Medicaid Prior Authorization Denials

MedCity News

AUGUST 17, 2023

It follows a report by the Office of Inspector General that found that Medicaid MCOs denied one out of every eight prior authorization requests in 2019. (D-New Jersey) announced that he is looking into high prior authorization denial rates by Medicaid managed care health plans.

Management

No digitization with HCP’s is not permanent

World of DTC Marketing

AUGUST 26, 2020

However, in both surveys, telehealth visits were perceived as more convenient than office visits (47% in May 2019 vs. 56% in June 2020).

Pharma Rep

Pharma Rep Pharma reps Doctors Physicians

Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years

Fierce Pharma

MARCH 19, 2024

After a year marked by Gilead's oncology push and an ongoing focus on CAR-T therapies, CEO Daniel O’Day collected his largest total compensation package since the year he arrived at the Califo | The CEO collected his highest total compensation package since his first year in the role in 2019.

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement

Fierce Pharma

JANUARY 3, 2024

After a dispute over milestone payments derailed a 2019 heart med collaboration, Daiichi Sankyo and Esperion Therapeutics have mended fences with a $125 million settlement. |

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

OCTOBER 18, 2023

Takeda ultimately purchased Shire for $62 billion in 2019. Back in 2018, Irish authorities hit Shire with a €398 million charge tied to that company’s rejection of AbbVie’s takeover bid in 2014.

AbbVie's rising star Skyrizi nabs key ulcerative colitis FDA approval

Fierce Pharma

JUNE 20, 2024

Since its original nod in 2019, AbbVie's IL-23 inhibitor has added several new uses over the years. AbbVie’s fast-growing Humira successor Skyrizi is already on a roll with skyrocketing sales. Now, its fourth approved disease area is ulcerative colitis.

FDA

FDA Sales

Humana Report: Health-related Social Needs Prevalent Among Dual-eligible and Non-dual-eligible MA Enrollees

MedCity News

JULY 10, 2023

A Humana study in Health Affairs found that 80% of dual-eligible beneficiaries had at least one health-related social need in 2019, compared to 48% of non-dual-eligible enrollees. While prevalence was higher in dual-eligible enrollees, non-dual-eligible enrollees shouldn’t be overlooked, researchers said.

Digital Health’s H1 Funding Landscape: Slimmer Checks, Fewer Deals & a Smaller Investor Pool

MedCity News

JULY 10, 2023

If things continue at the pace the sector has maintained throughout the first half of the year, 2023 will mark the field’s lowest yearly fundraising total since 2019, according to a new report.

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

MARCH 31, 2022

Between 2017 and 2019, pharmacy benefit managers’ gross profit increased by 12 percent despite PBM retention of manufacturer rebates decreasing during this period, according to a report released on Dec. The report showed that the PBM gross profit increased from $25 billion to $28 billion between 2017 and 2019.

Insurance

Insurance Prescription Manufacturing Sales

Gilead’s CMO to depart next year

PharmaVoice

JULY 19, 2024

Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.

Leads

Leads Medical

You can’t afford to get cancer

World of DTC Marketing

DECEMBER 13, 2021

OPENING: American cancer patients spent more than $21 billion on their care in 2019. From 2009 to 2019, the median monthly treatment costs for new drugs at launch reached $11,755 in the U.S… billion included out-of-pocket costs of $16.22 billion and patient time costs of $4.87 The post You can’t afford to get cancer.

Food and Drug Administration

Food and Drug Administration Food Medical Medicine

Adjusting Your Sales Approach- Questions Your Clients Have Right Now

Integrity Solutions

MARCH 30, 2020

Those business plans were created in Q4 2019, a quarter that started with the continuation of the greatest period of economic expansion and stock market growth in history. What kinds of questions were company leaders asking during that last quarter of 2019 when those 2020 plans were being put together?

Sales

Sales Competition Marketing Ethics

A perfect storm for biotech stocks

World of DTC Marketing

FEBRUARY 1, 2022

That’s significantly down from 2019, with 70 deals worth $261 billion. The last time the SPDR ETF suffered a drop of 15% or more was in 2018, and the fund followed it up with a 33% increase in 2019. There are reasons to believe that things could get better. For starters, biotech stocks rarely have two bad years in a row.

Food and Drug Administration

Food and Drug Administration FDA Pharmaceutical Food

Gun violence is a national health issue

World of DTC Marketing

MAY 25, 2022

There was nearly a 30 percent increase in homicides between 2019 and 2020, making it the most significant one-year increase in six decades. Gun violence isn’t just a criminal justice issue; it’s a public health issue. He and Ninez Ponce, Ph.D. Gun violence kills people. These are health impacts,” Dr. Rodriguez says.

Doctors

Doctors Healthcare Healthcare Physicians

Misjustice benefits pharma

World of DTC Marketing

JULY 6, 2022

The health sector led the federal and state lobbying spending in 2021, continuing a trend from 2019 and 2020. Once again money rules.

Pharma

Pharma Distribution Prescription Doctors

Our healthcare has failed us

World of DTC Marketing

SEPTEMBER 17, 2020

More recent state-level data from the 2019 Behavioral Risk Factor Surveillance System (BRFSS) confirm the trend that adult obesity rates continue to climb. In 2019, 12 states had obesity rates in the highest category for this survey (35 percent or greater), a jump from three states in 2014, and nine in 2018.

Healthcare

Healthcare Healthcare Insurance Healthcare Provider

Medical Devices Are Evolving Toward Specialized Solutions

MedCity News

JULY 27, 2023

In February of 2019, Johnson & Johnson acquired Auris Health and its FDA-cleared Monarch platform for $5.75 Later in 2019, Germany-based Siemens Healthineers announced its acquisition of Corindus and its FDA-cleared CorPath GRX System, a robotics platform specifically for percutaneous coronary interventions.

Specialization

Specialization Medical Medicine Leads

Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal

HHS: Younger Adults, Latino Individuals Showed Gains in Coverage From 2019 to 2021

Trending Sources

Galapagos CEO Tells JPM Audience the Rationale for Planned Business Separation

Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023

Forrester Research Report: How Sales and Marketing Intelligence Drive Improved Business Outcomes

Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline

Merck Neuroscience Acquisition Brings a Startup With Parkinson’s, ALS Programs

Blue Shield of California Adds Virta Health to Network for Diabetes Care

Medicaid MCOs Denied 1 out of 8 Prior Authorization Requests in 2019

The 2019 Technographic Data Report for B2B Sales Organizations

Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies

AstraZeneca’s Rare Disease Pipeline Notches Another FDA Approval

Disappointing data lead Pfizer to drop heart drug acquired as part of $11B deal

Boom, Now Bust: Budget Cuts and Layoffs Take Hold in Public Health

CVS Health reports 15.7% reduction in suicide attempts among Aetna members

Equip Expands Care to Adults, Banks Investment From General Catalyst

Lung cancer deaths decline but.

Vanda's jet-lag approval hopes for Hetlioz quashed with FDA hearing rejection

New FDA Nod for Roche Drug Moves It to the Front Line in Treating Blood Cancer

MA Beneficiaries Have Fewer In-Network Options for Psychiatrists Than Other Insurance Types

Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejection

BCBS Minnesota, Minnesota Oncology Achieve 10% Cost Reduction Through Value-based Contract

BCBS Massachusetts Ramps Up Mental Health Services After Seeing Visits Double

Daybreak Health Snags $13M For School-Based Mental Health Services

Sage, Biogen Drug Is Now the First Approved Oral Med for Postpartum Depression

NIH spending for drugs approved 2010-2019 lower than industry spending, study finds

Mass General Brigham-Born Revenue Cycle Company Snags $55M

Congressman Launches Investigation into Medicaid Prior Authorization Denials

No digitization with HCP’s is not permanent

Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M, his largest compensation package in years

Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

AbbVie's rising star Skyrizi nabs key ulcerative colitis FDA approval

Humana Report: Health-related Social Needs Prevalent Among Dual-eligible and Non-dual-eligible MA Enrollees

Digital Health’s H1 Funding Landscape: Slimmer Checks, Fewer Deals & a Smaller Investor Pool

Biden proposes subsidizing drug middlemen for insulin

Gilead’s CMO to depart next year

You can’t afford to get cancer

Adjusting Your Sales Approach- Questions Your Clients Have Right Now

A perfect storm for biotech stocks

Gun violence is a national health issue

Misjustice benefits pharma

Our healthcare has failed us

Medical Devices Are Evolving Toward Specialized Solutions

Stay Connected